Prevalence, characteristics and mortality rates of individuals eligible for lipid lowering using the JUPITER criteria in a general population sample
Abstract number: OC-WE-103
Cushman1 M., McClure2 L.A., Lakoski3 S.G., Jenny4 N.S.
11Department of Medicine, University of Vermont, Colchester 22Department of Biostatistics, University of Alabama at Birmingham, Birmingham 33Department of Medicine, University of Texas Southwestern, Dallas 44Department of Pathology, University of Vermont, Colchester, VT, USA
How-to-cite Cushman M, McClure LA, Lakoski SG, Jenny NS. Prevalence, characteristics and mortality rates of individuals eligible for lipid lowering using the JUPITER criteria in a general population sample. Journal of Thrombosis and Haemostasis 2009; Volume 7, Supplement 2: Abstract OC-WE-103
Background: The Justification of the Use of Statins in Primary Prevention: an Intervention Trial Using Rosuvastatin (JUPITER) trial recently reported reduction of cardiovascular and all cause mortality with statin treatment in patients with elevated C-reactive protein concentration who were not eligible for lipid-lowering treatment based on existing guidelines. We evaluated the impact of JUPITER entry criteria in a general population sample and determined mortality rates in those eligible or not eligible for statin treatment based on these criteria.
Methods: Participants were 11 339 participants of the REasons for Geographic And Racial Differences in Stroke (REGARDS) observational study cohort who were American men > 50, women > 65 years old without vascular diagnoses and not using lipid-lowering treatment at a baseline examination in their homes between 2003–2007.
Results: Among 11 339 participants, 21% (2342) met JUPITER entry criteria. Compared to JUPITER participants, these participants were more often women, black and had metabolic syndrome and used aspirin for cardioprotection. Over a median of 3.5 years follow-up, the mortality rate among REGARDS participants eligible for JUPITER was 1.17 per 100 person-years (95% CI 0.94–1.42). Compared to those otherwise eligible who had C-reactive protein < 2 mg/L (n = 2,620), those with C-reactive protein ≥ 2 mg/L (eg. trial eligible) had a multivariable-adjusted relative risk of 1.5 (95% CI, 1.1–2.2) for total mortality.
Conclusions: Among these men and women without cardiovascular disease, 21% would be newly eligible for lipid-lowering treatment based on JUPITER trial eligibility. Observed mortality rates suggest that if these criteria were used to prescribe lipid-lowering, there would be 2.3 fewer deaths per 1000 treated persons.
Disclosure of interest: none declared.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number
| Back to top